Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

Therapeutic Drug Monitoring

Volumn 38, Issue 4, 2016, Pages 432-438

  Van Bezooijen, Ji S ^a   Koch, Birgit C P ^a   Van Doorn, Martijn B A ^a   Prens, Errol P ^a   Van Gelder, Teun ^a   Schreurs, Marco W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adalimumab; biologics; ELISA; etanercept; infliximab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; DRUG MONITORING; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY TEST KIT; PRIORITY JOURNAL; PSORIASIS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; UVEITIS; BLOOD; METABOLISM; PHYSIOLOGY; PROCEDURES; RHEUMATOID ARTHRITIS;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS REACTIONS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETANERCEPT; HUMANS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84973889795     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000310     Document Type: Article

References (13)

1. Carrascosa JM, van Doorn MB, Lahfa M, et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014;28:1424-1430
2. Zandvliet ML, van Bezooijen JS, Bos MA, et al. Monitoring antigenspecific biologics: current knowledge and future prospects. Ther Drug Monit. 2013;35:588-594
3. Mosli MH, Sandborn WJ, Kim RB, et al. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109:994-1004
4. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284-288
5. Schouwenburg PA, van Stadt LA, Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72: 104-109
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305:1460-1468
7. Schmitz EM, van Kerkhof D, Hamann D, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2015
8. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765-771
9. Parussini E. Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays. Aliment Pharmacol Ther. 2013;37:281
10. Buurman DJ, Vande Casteele N, Sturkenboom MG, et al. Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays; authors' reply. Aliment Pharmacol Ther. 2013; 37:282
11. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-358
12. Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151:616-622
13. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013;35:530-538